Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab

Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab

To investigate whether peripheral blood biomarkers predict the outcome of anti-PD-1 antibody treatment for head and neck squamous cell carcinoma (HNSCC). Patients treated with nivolumab for platinum-refractory recurrent or metastatic HNSCC were retrospectively reviewed. Fifty-three patients treated...

Full description

Bibliographic Details
Main Authors: Daisuke Nishikawa, Hidenori Suzuki, Yusuke Koide, Shintaro Beppu, Shigenori Kadowaki, Michihiko Sone, Nobuhiro Hanai
Format: Article
Language:English
Published: MDPI AG 2018-11-01
Series:Cancers
Subjects:
nivolumab
head and neck
squamous cell carcinoma
prognostic factor
Online Access:https://www.mdpi.com/2072-6694/10/12/466

Similar Items

Similar Items